Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Prucalopride (Resolor®) is recommended as an option for use within NHS Wales for the treatment of chronic constipation in men in whom laxatives fail to provide adequate relief. |
|||
|
|||
Medicine details |
|||
| Medicine name | prucalopride (Resolor®) | ||
| Formulation | 1 mg, 2 mg film-coated tablet | ||
| Reference number | 918 | ||
| Indication | Treatment of chronic constipation in men in whom laxatives fail to provide adequate relief |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Gastro-intestinal system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0816 | ||
| NMG meeting date | 10/02/2016 | ||
| AWMSG meeting date | 23/03/2016 | ||
| Ratification by Welsh Government | 05/04/2016 | ||
| Date of issue | 06/04/2016 | ||
| Date of last review | 22/05/2019 | ||